Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.62 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.59 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.58 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.57 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.56 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9663959 | 1.00 | LTB4R (0.69) | LTB4RMAPTRXFP1FFAR1ALOX5 | |
| SCHEMBL9484086 | 1.00 | LTB4R (0.69) | LTB4RMAPTRXFP1FFAR1ALOX5 | |
| SCHEMBL8001859 | 1.00 | LTB4R (0.69) | LTB4RMAPTRXFP1FFAR1ALOX5 | |
| SCHEMBL1171967 | 0.98 | LTB4R (0.67) | LTB4RMAPTRXFP1FFAR1ALOX5 | |
| SCHEMBL503646 | 0.93 | ALOX5 (0.68) | LTB4RFFAR1ALOX5PDE4BF2RL1 | |
| SCHEMBL9664592 | 0.89 | F2RL1 (0.66) | LTB4RFFAR1ALOX5PDE4BF2RL1 | |
| SCHEMBL8843761 | 0.88 | CNR1 (0.60) | LTB4RFFAR1ALOX5PDE4BFFAR4 | |
| SCHEMBL11037985 | 0.87 | PLAAT3 (0.57) | LTB4RFFAR1ALOX5F2RL1CALM1 | |
| SCHEMBL10596837 | 0.87 | LTB4R (0.62) | LTB4RMAPTRXFP1FFAR1ALOX5 | |
| SCHEMBL11637942 | 0.86 | ALOX5 (0.59) | LTB4RMAPTALOX5F2RL1CALM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183221-A1 | PYRIDINE DERIVATIVE AND APPLICATION THEREOF | NICOYA THERAPEUTICS (SHANGHAI) CO., LTD (CN) | 2023-06-15 | — | — | US | disclosed |
| US-8124778-B2 | Tricyclic inhibitors of fatty acid amide hydrolase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124778-B2 | Tricyclic inhibitors of fatty acid amide hydrolase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124778-B2 | Tricyclic inhibitors of fatty acid amide hydrolase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100216750-A1 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216750-A1 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216750-A1 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-08-26 | — | — | US | disclosed |
| EP-2161997-A1 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | Boger, Dale L. (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2009113320-A1 | MMP INHIBITOR | 株式会社ヤクルト本社 (JP) | 2009-09-17 | — | — | WO | disclosed |
| WO-2008150492-A1 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008150492-A1 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-12-11 | — | — | WO | disclosed |
| US-5412144-A | Organic materials with nonlinear optical properties | THE BOARD OF TRUSTEES OF THE UNIV. OF ILLINOIS (US) | 1995-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216750-A1 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FADS1, FAAH, SCD | LTB4R 3660/4885MAPT 3956/4885RXFP1 2442/4885 |
| US-20230183221-A1 | PYRIDINE DERIVATIVE AND APPLICATION THEREOF | XDH, CYP11B2, DPYD | LTB4R 874/4885MAPT 2543/4885RXFP1 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.